Kodiak Sciences Earnings Call Transcripts
Fiscal Year 2026
-
Multiple late-stage retina programs are advancing rapidly, with key data readouts expected in 2024 and 2027. The portfolio targets large unmet needs with differentiated assets, and recent financing ensures funding through major milestones.
Fiscal Year 2025
-
Three major phase III readouts are expected in the next year, including GLOW2, DAYBREAK, and PEAK, with KSI-101 showing strong efficacy in MESI. KSI-101 is positioned as a first-line biologic, and commercial prospects are promising given the unmet need.
-
Three late-phase retinal assets are advancing, with tarcocimab and KSI-501 targeting the large anti-VEGF market and KSI-101 addressing MESI. Key phase III data readouts are expected in 2025–2026, supporting regulatory filings and potential revenue growth.
-
New phase I-B data for KSI-101 in MESI and DME show rapid, robust efficacy and a strong safety profile, with over 90% of MESI patients achieving fluid resolution and significant visual gains. Phase III PEAK and PINNACLE trials are underway, and KSI-101 is positioned to address a large unmet need in MESI with a differentiated dual mechanism.
-
Multiple phase III programs are progressing, with key data readouts for tarcocimab in DR and wet AMD expected in 2025 and 2026. Enhanced formulations aim to deliver best-in-class durability and efficacy, while KSI-101 advances in MESI with phase III data anticipated by end of 2026.
-
Retinal disease therapies face significant unmet needs in durability and efficacy, especially for diabetic retinopathy and inflammatory conditions. Three late-stage programs are advancing, with strong early data for KSI-101 and pivotal studies set for 2024. Cash runway extends into 2026.
Fiscal Year 2024
-
Multiple phase III studies for enhanced Tarcocimab and KSI-501 are nearing key milestones, with pivotal readouts expected in late 2025 and 2026. Innovative trial designs and strong physician enthusiasm support a robust regulatory strategy and future growth.
-
A diversified late-stage pipeline is advancing with enhanced formulations addressing prior efficacy and safety gaps. Key pivotal studies in diabetic retinopathy and wet AMD are set for enrollment completion in Q2 2025, with top-line data and BLA submission targeted for 2026.
-
Three late-stage programs with improved formulations and trial designs address prior gaps in retinal diseases. The company has commercial flexibility, strong cash reserves, proprietary manufacturing, and a robust platform. Key data readouts and potential product launches are expected between 2025 and 2026.
-
Three lead programs are advancing with improved formulations to address unmet needs in retinal diseases, supported by robust clinical data and a strong financial position. Two pivotal phase 3 studies are enrolling in 2024, with key data expected by late 2025 or early 2026.
-
Three late-stage clinical programs are advancing with enhanced formulations to address key retinal diseases, supported by strong preclinical and clinical data. Two pivotal phase 3 studies for tarcocimab are enrolling, with data expected in early 2026, and financial resources are sufficient to reach these milestones.